Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Sponsors Will Develop Plans To Target Dual-Eligibles, Panel Says

Executive Summary

Medicare Part D plan sponsors will develop specific prescription drug plans to target dual-eligible beneficiaries, panelists said during a Kaiser Family Foundation workshop on Medicare formularies March 14 in Washington, D.C

You may also be interested in...



Medicare Rx Premium Beats Projections Due To “Robust Competition”

The Centers for Medicare & Medicaid Services is playing up Part D premium levels as a sign that healthy competition among drug plans will help the program suit the pocketbooks of both beneficiaries and the federal government

Medicare Rx Premium Beats Projections Due To “Robust Competition”

The Centers for Medicare & Medicaid Services is playing up Part D premium levels as a sign that healthy competition among drug plans will help the program suit the pocketbooks of both beneficiaries and the federal government

CMS Medicare Formulary Reviews Include 14 Checkpoints

The Centers for Medicare & Medicaid Services has a 14-point checklist it is using in the review of Medicare Part D drug formularies

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel